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INTRODUCTION
Bronchiectasis is a respiratory disease characterized by irreversible dilatation of the airways, 
associated with chronic cough and sputum production.[1] Data from high-income countries 
(HICs) suggest a rising burden of bronchiectasis,[2-4] with severe disease associated with adverse 
patient outcomes including exacerbations, hospitalization, reduced quality of life, and increased 
mortality.[5-7]
ABSTRACT
Objectives: The survey was to determine Knowledge, attitude, and practices around bronchiectasis, as a starting 
point for the development of guidelines for care in African Countries.
Materials and Methods: This survey was administered to non-specialist physicians in urban health centers in 
Burkina Faso, Uganda, South Africa, and Ethiopia. Data were anonymized and analyzed at an individual level by 
country and health-care setting.
Results: A total of 388 participants were recruited from Ouagadougou (75/388, 19.3%), Kampala (85/388, 
21.9%), Johannesburg (74/388, 19.3%), and Addis Ababa (154/388, 39.6%). Median age was 30 years, and 66% 
were male, with a median of 3-year medical experience. Knowledge about the definition, clinical presentation, 
and diagnosis of disease was good. However, guidelines for local practice were largely absent. Wide variation was 
reported in diagnostic and management practices. Physicians recognized the need for guidelines and further 
training.
Conclusion: This study highlighted the lack of local guidelines for bronchiectasis care in these settings and 
marked variation in approaches to investigation, diagnosis, and management within and between sites. Context-
appropriate guidelines for bronchiectasis care in Sub-Saharan Africa are needed. These must be informed by local 
epidemiology, should reflect locally available resources and comorbidities including tuberculosis-disease, and 
should be codeveloped with local practitioners.
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However, very few data are available on the epidemiology 
of bronchiectasis in low- and middle-income countries 
(LMICs). This remains the case despite the high prevalence of 
risk factors including early childhood infections, pulmonary 
tuberculosis (TB), and HIV infection in these settings.[8-10] 
Emerging data from a new Indian Bronchiectasis Registry 
suggest that the epidemiology of disease in LMICs may 
be markedly different to that seen in HICs, with a higher 
proportion of younger male patients experiencing disease, 
frequently as a result of previous TB.[11] Outcomes associated 
with bronchiectasis in these settings remain unclear.
Guidelines for the diagnosis and management of 
bronchiectasis in routine clinical settings in LMICs are also 
limited. Guidelines used in HICs focus on individualized 
patient care and require specialist respiratory input.[12-14] 
These approaches are not easily applicable to LMICs where 
health care is largely decentralized and provided by general 
practitioners with little access to specialist care. Additional 
challenges faced in LMICs include the high prevalence of TB 
disease among those presenting with chronic cough[15] and 
the high burden of post-tuberculosis lung disease (PTLD) 
among TB survivors.[16]
Guidelines tailored to the diagnosis and management of 
bronchiectasis in resource-constrained settings are clearly 
needed, and a clear understanding of existing practices 
around bronchiectasis in LMICs will be a crucial starting 
point in their development. In this paper, we describe 
findings from a knowledge, attitudes, and practice (KAP) 
survey about bronchiectasis, completed among non-specialist 
doctors in four African cities.
MATERIALS AND METHODS
This cross-sectional study was completed in the four African 
cities of Addis Ababa (Ethiopia), Johannesburg (South 
Africa), Kampala (Uganda), and Ouagadougou (Burkina 
Faso) from March 2019 to April 2020.
A list of primary, secondary, and tertiary health facilities 
was compiled for each city from Ministry of Health and 
City Authority data. Public facilities were included in South 
Africa and Ethiopia, and private facilities were also included 
in Uganda and Burkina Faso. Facilities were convenience 
sampled from this list, based on ease of access, and were 
visited on a day convenient to the local investigator. All 
medical doctors who had completed a first degree, were 
working with adult medical patients, and were present on 
that day were eligible for inclusion. A pragmatic minimum 
sample size of 40 participants was agreed per city, and 
sampling continued until this number was met.
All participants were asked to complete a study questionnaire, 
which was developed by the study team based on the British 
Thoracic Guideline for Bronchiectasis[17] and personal 
experience of the local study leads. This included questions 
about bronchiectasis knowledge (definition, clinical 
presentation, diagnosis, and basic management), attitudes 
(beliefs about the importance of the condition and standards 
of training), and current clinical practice (availability of 
guidelines, access to diagnostic and management tools, and 
antibiotic use). The questionnaire was developed in English 
and translated into French for use in Burkina Faso by the local 
PI (ARO) with review by a professional translation service. 
Paper questionnaires were administered to participants in 
English or French and were self-completed by participants, 
with immediate return to the study team to be checked for 
missing data. Neither participant nor health facility names 
were included on the questionnaire, to ensure anonymity. 
Participants in Uganda received $3 each for participating in 
the study as required by the local IRB.
Quantitative data were analyzed using Epi Info 7.2 and 
R-studio. Data were described by country and health-care 
facility type. Chi-square or Fisher’s exact tests were used to 
compare categorical variables, and ANOVA used to compare 
continuous parameters between groups. Ethics approval 
was obtained from the Institutional Review Boards in each 
country (Burkina Faso: 2019-3-038; Ethiopia: IMR/264/11; 
Uganda: MHREC 1649; and South Africa: HREC: M190753). 
Permission was sought from heads of facilities before data 




A total of 388 participants were recruited from Burkina 
Faso (75/388, 19.3%), Uganda (85/388, 21.9%), South Africa 
(74/388, 19.3%), and Ethiopia (154/388, 39.6%). Median 
age was 30 years (IQR: 28–33 years), and 66% were male. 
On average, participants had been working for a median of 
3 years (IQR: 2–6). However, marked variation was observed 
between sites with those in South Africa older, with a longer 
duration in practice, and more likely to be working in tertiary 
care facilities. All participants in Ethiopia and South Africa 
were recruited from the public sector while 72.1% (49/75) 
and 27.9% (19/85) of participants in Burkina Faso and 
Uganda were recruited from the private sector, respectively 
[Table 1].
Knowledge
The majority of participants (333/388, 85.8%) knew that 
bronchiectasis is defined by chronic irreversible dilatation of the 
airways. Participants who selected an incorrect definition were 
marginally older than those who chose the correct definition 
(32 years [IQR: 29–39.5] vs. 30 years [28–32], P < 0.001), but no 
differences were noted by health facility type [Table 2].
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Male n (%) 256 (66.0) 53 (70.7) 106 (68.8) 42 (56.7) 55 (64.7) 0.278
Age (years) (median, IQR) 30 (28–33) 30 (29–33) 28 (27–30) 33 (31–39) 30 (28–34) <0.001
Health facility setting (n, %)
Primary 37 (9.5) 6 (8.0) 22 (14.3) 2 (2.7) 7 (8.2) <0.001
Secondary 173 (4.6) 18 (24.0) 86 (55.8) 28 (37.8%) 41 (48.2)
Tertiary 110 (28.4) 2 (2.7) 46 (29.9) 44 (59.5) 18 (21.2)
Private 68 (17.5%) 49 (65.3%) 0 (0.0%) 0 (0.0%) 19 (22.4)
Years in practice (median, IQR) 3 (2–6) 2 (1–3) 2 (2–4) 8 (6–13) 4 (2–6) <0.001
Most participants (356/388, 91.7%) also knew that the 
diagnosis of bronchiectasis is based on imaging, with 
computerized tomography (CT) identified as the gold 
standard diagnostic tool by 87.0% (310/356). However, only 
half (200/388, 51.5%) correctly identified ring and tramlines 
as the dominant feature of bronchiectasis seen on plain 
CXR. This proportion was highest in tertiary health facilities 
(75/111, 67.6%) [Figure  1], and among those practitioners 
from facilities with CXR capacity, compared to those without 
(184/345 [53.3%] vs. 10/38 [26.3%], P = 0.003).
The most common risk factors identified for bronchiectasis 
were TB (327/388, 84.3%) and childhood chest infections 
(212/388, 54.6%). HIV was identified as a common risk 
factor by less than a third of practitioners in Burkina Faso 
(23/75, 30.7%) and Ethiopia (42/154, 27.3%), but over half 
of those in Uganda (43/85, 50.5%) and South Africa (53/74, 
71.6%).
Clinical features of both disease and exacerbations were well 
recognized: Chronic productive cough was widely identified 
as the most common symptom of disease by 94.1% (365/388), 
with increased sputum volume and breathlessness correctly 
identified as common features of exacerbation by 84.8% 
(329/388) and 73.7% (286/388), respectively. The majority of 
participants (323/388, 83.2%) recognized that patients with 
bronchiectasis are at risk of recurrent chest infections.
Knowledge about recommended investigations and 
management varied widely. When asked which laboratory 
tests should be completed as part of a standard “workup” for 
bronchiectasis, sputum mycobacterial culture was selected by 
54.1% (20/37), 74.0% (128/173), 82.9% (92/111), and 85.3% 
(58/68) of respondents from primary, secondary, tertiary, 
and private care settings, respectively [Table 2].
Among the therapy options presented to participants, daily 
airway clearance and antibiotics during exacerbations were 
selected as the most important measures by 55.3% (215/389) 
and 50.1% (195/389) of participants. Over half (214/388, 
55.1%) reported that the recommended antibiotic duration 
was 10–14 days, while 12.8% (50/359) chose >14 days and 
7.5% (29/385) chose 5 days.
Figure 1: Dominant feature of bronchiectasis on CXR selected by 
participants, by health facility setting.
Attitudes
Almost two-thirds of participants (243/387, 62.8%) 
somewhat or strongly agreed that bronchiectasis is a common 
condition among adults in their setting. However, this 
proportion varied widely from Burkina Faso (9/75, 12.0%) to 
South Africa (69/74, 93.3%). The majority of participants in 
all countries (374/387, 96.9%) felt that general practitioners 
in their setting need more training on the diagnosis and 
management of bronchiectasis. Similarly, 82.0% (373/387) 
strongly agreed that local guidelines for the diagnosis and 
management of bronchiectasis are needed.
Practice
Overall only 17.3% (67/387) of participants had guidelines 
or protocols to follow when managing patients with 
bronchiectasis. Substantial variation was seen between 
countries: Very few practitioners in Burkina Faso had 
access to guidelines (1/75, 1.3%), while 29.7% (22/74) in 
South Africa and 22.9% (35/153) in Ethiopia reported that 
these were available. The majority of those who had access 
to guidelines were based in secondary and tertiary centers 
(53/57, 93.0%). The guidelines referred to included Ugandan 
and Ethiopian National guidelines or “Standard treatment” 
guidelines, documents from the World Health Organization 
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or the British Thoracic Society, and the evidence database 
“UpToDate” (Wolters Kluwer, Waltham, MA, USA).
The majority of practitioners in all countries had access to 
blood tests (346/388, 89.2%), oxygen saturation measurement 
(341/388, 87.9%), and plain chest radiographs (350/388, 
90.2%) within their health facilities. Only 19.5% (76/389) and 
12.6% (49/389) of participants reported access to spirometry 
and full lung function testing, respectively. Sputum 
culture was easier to access in South Africa compared to 
elsewhere, including both routine (93.3% [70/75] vs. 25.5% 
[80/314], P < 0.001) and TB culture (78.7% [59/75] vs. 32.5% 
[102/314], P < 0.001) [Table  3]. CT imaging was available 
largely to practitioners from South Africa, and those working 
in the private sector in Burkina Faso and Uganda, with only 
11.8% (29/246) of practitioners in the public sector outside of 
South Africa able to access this.
A wide range of antibiotics are being used for the treatment 
of exacerbations [Figure  2]. The most common agent was 
oral co-amoxiclav, used by 64.8% (252/389). Piperacillin/
tazobactam was reported by 10 participants located in 
Uganda or South Africa, and Meropenem use was reported 
by 12 practitioners spread across all health facility types 
in Uganda. Ciprofloxacin use was lower in South Africa, 
compared to other countries (14.7% [11/75] vs. 45.5% 
[143/314], P < 0.001). Access to chest physiotherapy was 














Chronic irreversible airway dilatation 333 (85.8) 70 (93.3) 142 (92.8) 61 (82.4) 60 (70.6) <0.001
Reversible airway dilatation 25 (6.4) 4 (5.3) 5 (3.2) 3 (4.1) 13 (15.3)
Scarring/fibrosis of lung tissue 24 (6.2) 0 (0) 6 (3.9) 10 (13.5) 8 (9.4)
Consolidation within lung tissue 6 (1.6) 1 (1.3) 1 (0.6) 0 (0) 4 (4.7)
Gold standard diagnostic test (n, %)
Chest CT scan 310 (79.9) 47 (62.7) 136 (88.3) 61 (82.4) 66 (77.6) <0.001
CXR 46 (11.9) 21 (28.0) 5 (3.2) 9 (12.1) 11 (12.9)
Lung function 17 (4.4) 6 (8.0) 4 (2.6) 1 (1.4) 6 (7.1)
Spirometry 15( 3.9) 1 (1.3) 9 (5.8) 3 (4.1) 2 (2.4)
Main sign on CXR (n, %)
Consolidation 107 (27.6) 49 (65.3) 25 (16.2) 5 (6.8) 28 (33.3) <0.001
Ring and tramlines 200 (51.5) 23 (30.7) 91 (59.1) 50 (67.6) 36 (42.9)
Volume loss 24 (6.2) 0 (0) 12 (7.8) 5 (6.8) 7 (8.3)
Cavities 50 (12.9) 1 (2.3) 26 (16.9) 18 (24.3) 5 (6.0)
None 22 (5.7) 2 (2.7) 12 (7.8) 0 (0) 8 (9.5)
Common risk factors (n, %)
Childhood chest infections 212 (54.6) 56 (74.7) 65 (42.2) 49 (66.2) 42 (49.4) <0.001
TB 327 (84.3) 62 (82.7) 121 (78.6) 70 (94.6) 74 (87.1) <0.001
HIV 160 (41.2) 23 (30.7) 42 (27.3) 52 (70.3) 43 (50.6) <0.001
Asthma 147 (37.9) 35 (46.7) 72 (46.7) 11 (14.9) 85 (34.1) <0.001
Allergic bronchopulmonary aspergillosis 171 (44.1) 37 (49.3) 67 (43.5) 21 (28.3) 46 (54.1) 0.007
Three most important therapies (n, %)
Daily airway clearance 215 (55.4) 41 (54.7) 83 (53.9) 59 (79.7) 32 (37.6) <0.001
Decreasing amount of activity 57 (14.7) 27 (36.0) 20 (13.0) 1 (1.3) 9 (10.6) <0.001
Daily antibiotics 110 (28.3) 21 (28.0) 50 (32.5) 2 (2.7) 37 (4.4) <0.001
Antibiotics during exacerbations 194 (50.0) 40 (53.3) 92 (59.7) 32 (44.2) 30 (35.3) 0.002
Inhaled corticosteroids 126 (32.5) 34 (45.3) 63 (40.9) 2 (2.7) 27 (31.8) <0.001
Inhaled bronchodilators 89 (22.9) 24 (32.0) 39 (25.3) 4 (5.4) 22 (25.9) <0.001
Vaccination pneumococcal and influenza 92 (23.7) 16 (21.3) 23 (14.9) 46 (62.7) 7 (8.2) <0.001
Recurrent TB treatment 15 (3.9) 4 (5.3) 5 (3.2) 1 (1.3) 5 (5.9) 0.406
Recommended duration of antibiotics for exacerbations (n, %)
5 days 29 (7.5) 0 (0) 3 (2.0) 18 (24.3) 8 (9.4) <0.001
7 days 94 (24.2) 10 (13.0) 41 (26.8) 21 (28.4) 22 (25.9)
10–14 days 214 (55.1) 45 (60.0) 98 (64.1) 27 (36.5) 43 (50.6)
>14 days 50 (12.9) 19 (25.3) 11 (7.2) 8 (10.8) 12 (14.1)
None 1 (0.3) 1 (1.3) 0 (0) 0 (0) 0 (0)
TB: Tuberculosis
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Guidelines/protocol followed for patient 
management (n, %)
n=387* n=153* n=85
Yes 67 (17.3) 1 (1.3) 35 (22.9) 22 (29.7) 9 (10.6) <0.001
No 232 (60.0) 52 (69.3) 85 (55.5) 36 (48.6) 59 (69.4)
Not sure 88 (22.7) 22 (29.3) 33 (21.6) 16 (21.6) 17 (20.0)
Tools available for patient assessment, within health facility (n, %)
Oxygen saturation 341 (87.9) 59 (78.7) 135 (87.7) 67 (90.5) 80 (94.1) 0.022
Spirometry 75 (19.3) 18 (24.0) 8 (5.2) 44 (59.4) 5 (5.9) <0.001
Full lung function (lung volumes +/− gas transfer) 49 (12.6) 2 (2.7) 5 (3.2) 36 (48.6) 6 (7.1) <0.001
Blood tests (FBC, renal function, liver function) 346 (89.2) 66 (88.0) 134 (87.0) 70 (94.6) 76 (89.4) 0.544
Sputum culture for respiratory organisms 149 (38.4) 25 (33.3) 24 (15.6) 69 (93.2) 31 (36.5) <0.001
Sputum culture for Mycobacterium tuberculosis 160 (41.2) 23 (30.7) 36 (23.4) 58 (78.4) 43 (50.6) <0.001
CXR 350 (90.2) 60 (80.0) 140 (90.1) 73 (98.6) 77 (90.6) <0.001
CT imaging 125 (32.2) 27 (36.0) 18 (11.7) 60 (81.1) 20 (23.5) <0.001
Access to chest physiotherapy services (n, %) n=384* n=152* n=73* n=84*
Yes 136 (35.4) 18 (24.0) 23 (15.1) 66 (90.5) 29 (34.5) <0.001
No 199 (51.8) 42 (56.0) 111 (73.0) 4 (5.4) 42 (50.0)
Not sure 49 (12.8) 15 (20.0) 18 (11.9) 3 (4.1) 13 (15.5)
*Missing data for this question
Figure  2: Proportion of participants reporting use of various 
antibiotics and routes, across all countries.
compared to 22.5% (70/311) of practitioners elsewhere. 
However, among those with access, only 53.3% (73/137) 
routinely refer patients for chest physiotherapy treatment.
DISCUSSION
In this paper, we explore KAPs about bronchiectasis among 
non-specialist doctors in four African cities. Our findings 
suggest good knowledge about bronchiectasis, its definition, 
and common risk factors. However, guidelines for local 
practice were absent, with variation observed in diagnostic 
and management practices, and reliance on approaches 
recommended for HICs with little adaptation to local 
resource capacity.
Participants displayed reasonable knowledge about the 
diagnosis and definitions of bronchiectasis – the majority 
were aware of CT imaging as the gold standard for diagnosis, 
correctly identified symptoms of disease and exacerbations, and 
knew that recurrent infections may be a consequence of disease.
TB was correctly recognized as an important risk factor 
by 84% of participants. TB incidence lies between 48 and 
500/100,000 in these four countries,[18] and over a third of 
adult pulmonary TB survivors are thought to have residual 
bronchiectasis,[16,19,20] such that it is indeed likely that TB is 
a dominant risk factor for airways disease in these settings. 
Similarly, chronic HIV infection has been associated with 
small and large airway pathology,[8] and the recognition 
of HIV as a risk factor for bronchiectasis increased with 
the population prevalence: Under a third recognized HIV 
as a common risk factor in Burkina Faso and Ethiopia 
(HIV prevalence 0.7% and 1.0%), but 50–70% identified 
it as a common risk factor in Uganda and South Africa 
(HIV prevalence 6.5% and 20.4%).[16] However, only half of 
participants identified childhood infections as a common 
cause of disease, while ABPA and asthma were identified 
by approximately 40% of participants. Data from a recently 
established Indian bronchiectasis registry suggest that almost 
a quarter of disease in India is post-infectious, while <10% 
is related to ABPA and 2.5% to asthma and it is likely that 
patterns may be similar in Africa.[21] If true, the understanding 
of risk factors among practitioners in this study may reflect 
the dominance of bronchiectasis literature focused on HICs, 
where airways disease may be relatively more important.
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Variation was observed in approaches to diagnosis and 
management, and may reflect the lack of established patient 
pathways and guidelines for bronchiectasis care. Less than a 
fifth of participants overall had access to any guidelines, and 
among those that did, many were using documents produced 
by organizations which are largely focused on care in HICs.
Knowledge of diagnosis and investigations for bronchiectasis 
appeared correspondingly poorly tailored to the LMIC 
context. Although CXR was the only imaging modality 
available to the majority of practitioners, only half knew 
that ring and tramline changes are the pathognomonic 
appearance of bronchiectasis on CXR. Despite being in 
high TB burden settings, only half to three quarters of 
participants in primary and secondary care selected sputum 
mycobacterial culture as a relevant investigation to perform 
in the work-up of patients.
Use of locally appropriate strategies for bronchiectasis 
management was also limited. Airway clearance exercises 
are a mainstay of bronchiectasis treatment in international 
treatment guidelines.[12,13] They are cheap and can be 
performed independently with minimal equipment, making 
them a feasible management option in LMICs. However, only 
half of participants identified regular airway clearance as a 
management priority, with little access to chest physiotherapy 
outside of South Africa.
Use of antibiotics for exacerbations was identified as a 
management priority by only half of participants, and the 
antibiotic agents and treatment durations used for exacerbations 
varied widely. The widespread use of ciprofloxacin – a 
fluoroquinolone with activity against Mycobacterium 
tuberculosis – is worrying in high TB incidence settings, as 
was the reported use of carbapenems even in primary care 
settings in Uganda. Access to sputum culture in settings outside 
of South Africa was limited, and microbiological data are, 
therefore, needed to guide empirical antibiotic use and prevent 
emergence of antimicrobial resistance.[22]
Finally, the proportion of participants who felt that 
bronchiectasis was common in their setting varied from 
just 12% in Burkina Faso to 93% in South Africa. This may 
reflect differences in medical training or the true burden of 
disease in these settings, perhaps as a result of the variation 
in TB incidence from 48/100,000 to 500/100,000 between 
these settings.[23] More data on the epidemiology of disease 
are required to determine this. However, the majority of 
the study participants in all settings would welcome more 
training and clear guidelines for management.
This study had several limitations. No standardized tool was 
available to assess KAP about bronchiectasis. The health 
facilities included were convenience sampled, based in urban 
areas, and relatively well resourced, and findings cannot be 
generalized to rural or less well-resourced settings. Data from 
practitioners were analyzed at an individual rather than facility 
level, and so “clustering” of findings by facility cannot be 
assessed. While participants were asked about their knowledge 
and practice, routine practice was not observed, and there may 
have been reporting bias. Finally, in this study, we assessed 
knowledge and practice of a specific type of pathology – 
bronchiectasis – but local practitioners may have been more 
familiar with syndromic descriptions of disease using terms 
such as “chronic cough” or “PTLD,” and questionnaire answers 
may have been different if these terms had been used.
Strengths of this study include our focus on a hitherto 
neglected disease in Africa, inclusion of non-specialist 
practitioners who are responsible for the majority of care in 
these settings, and large sample size. The survey covered a 
range of subjects relevant to the development of guidelines 
and training materials.
Our findings have several implications. First, there is a clear 
need for context-appropriate guidelines for bronchiectasis 
care in these settings. We suggest that these guidelines 
should be informed by data on local epidemiology and 
codeveloped with local practitioners. They should be 
suitable for decentralized care, with emphasis on low-cost 
patient-centered interventions such as chest physiotherapy, 
and with recommendations for appropriate antibiotic use. 
Consideration should be given to whether these guidelines 
are best targeted at syndromes such as “chronic cough” or 
PTLD, or at bronchiectasis itself, but whatever the approach, 
care should be taken to prioritize investigation and treatment 
for active TB disease in all adults presenting with chronic 
cough in high TB incidence settings. Finally, we call on the 
international community of bronchiectasis researchers to 
ensure broader representation of LMICs in bronchiectasis 
disease registries and research collaborations to ensure that 
low-resource settings are not left behind as management of 
this important chronic condition progresses.
CONCLUSION
This study identified the knowledge, attitude and practice 
gaps in the management of bronchiectasis in Sub-Saharan 
Africa. These gaps may be related to the lack of data about 
the epidemiology of the disease in the region and deficit 
of guidelines for its management. Our findings suggest the 
need for guidelines for local investigation, diagnosis and 
management as per the resource availability in the region. 
Further studies are needed to describe disease epidemiology 
and current management practices in both urban and rural 
settings in sub-Saharan Africa.
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